SABS SAB Biotherapeutics Inc
Price (delayed)
$2.68
Market cap
$24.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.17
Enterprise value
$12.83M
Highlights
The EPS has increased by 8% QoQ
SAB Biotherapeutics's equity has surged by 134% YoY but it has decreased by 13% QoQ
SAB Biotherapeutics's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
SAB Biotherapeutics's net income has decreased by 38% YoY
The company's debt rose by 9% YoY
Key stats
What are the main financial stats of SABS
Market
Valuations
Earnings
Shares outstanding
9.23M
Market cap
$24.73M
Enterprise value
$12.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
8.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.62
Revenue
$2.78M
EBIT
-$40M
EBITDA
-$35.03M
Free cash flow
-$37.37M
Per share
Balance sheet
Liquidity
EPS
-$6.17
Free cash flow per share
-$4.04
Book value per share
$5
Revenue per share
$0.3
TBVPS
$6.69
Total assets
$61.89M
Total liabilities
$15.77M
Debt
$5.34M
Equity
$46.12M
Working capital
$32.03M
Debt to equity
0.12
Current ratio
5.24
Quick ratio
4.94
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
-1,260.2%
Gross margin
100%
Net margin
-1,450.3%
Operating margin
-1,647%
Return on assets
-65.7%
Return on equity
-94%
Return on invested capital
-113.7%
Return on capital employed
-73.6%
Return on sales
-1,438.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SABS stock price
How has the SAB Biotherapeutics stock price performed over time
Intraday
-3.94%
1 week
-7.9%
1 month
10.29%
1 year
-58.77%
YTD
-61.05%
QTD
-13.55%
Financial performance
How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$2.78M
Gross profit
$2.78M
Operating income
-$45.79M
Net income
-$40.32M
Gross margin
100%
Net margin
-1,450.3%
SAB Biotherapeutics's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
SAB Biotherapeutics's gross profit has shrunk by 57% YoY but it has increased by 7% QoQ
SABS's operating income has plunged by 55% YoY and by 9% from the previous quarter
SAB Biotherapeutics's net income has decreased by 38% YoY
Growth
What is SAB Biotherapeutics's growth rate over time
Valuation
What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
8.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.62
The EPS has increased by 8% QoQ
SAB Biotherapeutics's equity has surged by 134% YoY but it has decreased by 13% QoQ
The P/B is 49% below the last 4 quarters average of 1.1
SAB Biotherapeutics's revenue has shrunk by 57% YoY but it has increased by 7% QoQ
The P/S is 28% below the last 4 quarters average of 12.9
Efficiency
How efficient is SAB Biotherapeutics business performance
The ROE has grown by 15% YoY and by 14% from the previous quarter
SAB Biotherapeutics's ROIC has increased by 14% from the previous quarter
SABS's ROA is up by 10% from the previous quarter but it is down by 2.2% YoY
The ROS has increased by 5% QoQ
Dividends
What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SABS.
Financial health
How did SAB Biotherapeutics financials performed over time
The company's total assets has surged by 75% YoY but it fell by 13% QoQ
The total liabilities has declined by 15% since the previous quarter
The company's debt is 88% lower than its equity
SAB Biotherapeutics's equity has surged by 134% YoY but it has decreased by 13% QoQ
SABS's debt to equity has dropped by 52% year-on-year but it is up by 20% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.